 Today I have the pleasure of speaking with E-Research's Chris Thompson. How are you today, Chris? Great, Tracy. How about you? Well, I see that you have an update on Zortex Therapeutics. We've got a $26 buy recommendation. Yes? Yes, that's correct. Well, I only say that because if you look at the stock price now, I mean, this is eight times your money. Yes. So it's one of these biotech pharma companies which is moving into stage three. So revenue is a couple of years down the road. They're looking at potentially some revenue maybe in 2023, 2022. So that's why it's a little bit further. A price target, there's a little risk involved as a stage three company. Well, I have to tell you, one of the many things that I love about E-Research reports, can't say enough nice things about them is I love your investment highlights and the way that you break them down. So do you mind if we just go through some of the high points? Because obviously, investor intel members, you should read this information. If you have any questions, just send Chris an email. You've got the very simply highlights. You want to give us one of the best? Yes. So the thing about Zortex is it's taking an existing drug that was used to treat gout and repurposing it for other diseases. So that takes a little bit of the risk out of the situation. The drug is oxypyrinol and what they were targeting this drug was elevated uric acid and the effects on kidneys and kidney disease is a huge problem. And so what they're going after is reusing this drug with a new formulation and that's their intellectual property but targeting high uric acids and the effect on kidneys. Well, that must be an absolutely huge market gout with all of us overweight. Our numbers are shocking and our aging population. This must be a substantial market to go after. Yes. So they're going after the acute kidney injury market using this existing drug. And the interesting thing was is that when COVID happened, they noticed a correlation between COVID and kidney injury. And so now they've done a new formulation to go after the treatment of COVID as well. Sorry, the kidney impacts because of the COVID disease. So as you say, this market was large to begin with and now it's actually got an added effect with the COVID illness and how they can help those people recover who have had COVID. And of course, the balance sheet is strengthened. Talk to us about that. Yeah. So Zortex is a Canadian company. It was listed in Canada and over the market. But recently, they did an uplisting to NASDAQ and raised about $21 million in total. And they're going to use those funds as they move towards the stage three trials for the drugs, which is a fully sort of funded balance sheet for them and can carry them right through to this drug going to commercial production. And in this case, Zortex will not be the manufacturer, but they will contract or they are looking right now to contract with a third party who will actually produce the drugs once they get it approved. Well, one of the many things that I've noticed on this is they're both CSC and NASDAQ. Most companies are TSX and NASDAQ. Any reason why they are they planning on maintaining that or have they commented on that? Yeah, actually, they just switched over. So on the next report that would come out, we'll have an updated ticker, but the Canadian ticker has now gone over to the TSX venture exchange. The ticker symbol is XRTX on the TSXB now. And they will have the two listings, both the venture listing in Canada as well as the NASDAQ listing in the US. Also, I noticed in your financial analysis and valuation highlights, you have in upper caps significantly undervaluated and bolded, we reiterate our buy rating. Any comments on that? Yeah, just when you're looking at comparable companies in the US, they're at a much higher valuation right now from a market cap standpoint for this stage of company. As I mentioned before, they have two drugs at stage three. And so when you're looking at the market cap, you're sub $50 million, of course, depending on what it's trading at today. But you're looking at comparable companies in the US and they are north of $100 million. And that's partially why they did the US listing, was to get some more institutional investors from the US, because they are under valued and in comparison to their competitors. Well, as always, we at Investor Intel follow your reports, Chris. Thank you so much for providing us with a little bit more color with your update on your XRTX, XRTX Therapeutics Research Report. And I hope anyone out there wants to learn more, go to your website. Yeah. Thanks, Tracy. Yeah, you can go to the website and you can download the report there. It's available for free.